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A B S T R A C T
Background: New tuberculosis (TB) drug treatment regimens are urgently needed. This study evaluated
the potential of the histone deacetylase inhibitors (HDIs) valproic acid (VPA) and suberoylanilide
hydroxamic acid (SAHA) to enhance the effects of ﬁrst-line anti-TB drugs against intracellular
Mycobacterium tuberculosis.
Methods: M. tuberculosis H37Rv cultures were exposed to VPA or SAHA over 6 days, in the presence or
absence of isoniazid (INH) and rifampicin (RIF). The efﬁcacy of VPA and SAHA against intracellular M.
tuberculosis with and without INH or RIF was tested by treating infected macrophages. Bactericidal
activity was assessed by counting mycobacterial colony-forming units (CFU).
Results: VPA treatment exhibited superior bactericidal activity to SAHA (2-log CFU reduction), while both
HDIs moderately improved the activity of RIF against extracellular M. tuberculosis. The bactericidal effect
of VPA against intracellular M. tuberculosis was greater than that of SAHA (1-log CFU reduction) and
equalled that of INH (1.5-log CFU reduction). INH/RIF and VPA/SAHA combination treatment inhibited
intracellular M. tuberculosis survival in a shorter time span than monotherapy (3 days vs. 6 days).
Conclusions: VPA and SAHA have adjunctive potential to World Health Organization-recommended TB
treatment regimens. Clinical evaluation of the two drugs with regard to reducing the treatment duration
and improving treatment outcomes in TB is warranted.
© 2018 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Tuberculosis (TB) continues to cause 1.5 million deaths every
year (WHO, 2015a). Although efforts to bring to the market new
chemotherapeutic agents targeting the aetiological agent of TB
(Mycobacterium tuberculosis) are ongoing, the protracted and
expensive drug development process, coupled with a high attrition
rate of new drug compounds, has hindered progress in the
development of new anti-TB drugs. Efforts towards developing
new TB treatment regimens to reduce the duration of treatment
and improve treatment outcomes (mortality and long-term
pulmonary complications (Manji et al., 2016)), particularly for
drug-resistant TB, have focused attention on the repurposing of
safe drugs commonly used in medical practice worldwide that are* Corresponding author at: KHNW, Frankfurt, Germany and Champalimaud
Foundation, Lisbon, Portugal.
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creativecommons.org/licenses/by-nc-nd/4.0/).already approved by the United States Food and Drug Administra-
tion (FDA) for administration as adjuncts to TB therapy (Zumla
et al., 2016). Some noteworthy examples include ibuprofen
(Vilaplana et al., 2013), acetylsalicylic acid (Tobin et al., 2012;
Byrne et al., 2007), simvastatin (Skerry et al., 2014), metformin
(Singhal et al., 2014), and phenylbutyrate (Mily et al., 2015). These
drugs may also act in a host-directed fashion (i.e., immune
modulation) in concert with standard anti-mycobacterial drugs,
thus engaging an additional avenue of ameliorating disease
burden.
Various therapeutic agents licensed for non-TB indications
appear to be promising against drug-sensitive as well as drug-
resistant strains of M. tuberculosis (Kaufmann et al., 2014). Clinical
testing of the histone deacetylase inhibitor (HDI) phenylbutyrate
in patients with pulmonary TB has shown promising preliminary
results, augmenting an inhibitory effect against M. tuberculosis
growth with host macrophage immune responses (Mily et al.,
2015; Coussens et al., 2015). HDIs increase the acetylation of lysineious Diseases. This is an open access article under the CC BY-NC-ND license (http://
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gene transcription, thus modifying gene expression (Haery et al.,
2015).
Numerous HDIs are being actively explored for cancer therapy
(Haery et al., 2015), among which are valproic acid (VPA) and
suberoylanilide hydroxamic acid (SAHA/vorinostat). VPA is cur-
rently used as an anticonvulsant, and studies are simultaneously
testing its clinical efﬁcacy against several types of solid tumour and
lymphoma (Haery et al., 2015). SAHA received FDA approval in
2006 for the treatment of cutaneous T-cell lymphoma (CTCL),
while further clinical trials are underway to evaluate its adjunctive
capacity against a myriad of solid tumours (Haery et al., 2015).
Importantly, VPA and SAHA have also shown therapeutic potential
against several infections. SAHA can trigger the reactivation of
latent HIV-1 infection in human CD4 T cells (Archin et al., 2009),
exposing viral progeny to antiretroviral drugs, and is currently
under clinical investigation (clinicaltrials.gov identiﬁer:
NCT01319383, NCT01365065). SAHA has also shown activity
against West Nile virus (WNV) replication and associated disease
in experimental mice (Nelson et al., 2015). VPA can also promote
latent HIV-1 reactivation (Zeng et al., 2014), and has been shown to
induce the disruption of WNV infection of kidney cell lines derived
from monkey and hamster, as well as the abrogation of herpes
simplex virus 1 (HSV-1) infection of a human oligodendrocyte cell
line (Crespillo et al., 2016).
This study evaluated the potential of VPA and SAHA as adjunct
therapy for enhancing the effects of the two main ﬁrst-line anti-TB
drugs, namely isoniazid (INH) and rifampicin (RIF), against
extracellular as well as intracellular M. tuberculosis.Figure 1. Anti-mycobacterial activity of isoniazid (INH), rifampicin (RIF), valproic acid (VP
in liquid culture when exposed individually. Extracellular M. tuberculosis in mycoba
concentrations (1.18 mM and 5.90 mM) (B), or SAHA, also at two different concentratio
correspond to the World Health Organization-recommended standards (INH 0.1 mg/m
bactericidal activity. Mean and SEM of two independent experiments analysed using tMaterials and methods
Reagents and culture media
Middlebrook 7H9 liquid medium supplemented with 10% oleic
acid–albumin–dextrose–catalase (OADC), 2% glycerol, and 0.05%
Tween 80 (7H9C), as well as Middlebrook 7H11 solid medium
supplemented with 10% OADC and 2% glycerol (7H11C), were
purchased from the Karolinska University Hospital substrate unit.
RPMI Glutamax medium, foetal bovine serum (FBS), and anti-
biotics (penicillin/streptomycin) for tissue culture were purchased
from Life Technologies. Phorbol myristate (PMA), VPA, SAHA, INH,
and RIF were purchased from Sigma-Aldrich. SAHA, INH, and RIF
stocks were prepared in dimethyl sulfoxide (DMSO), while VPA
stocks were prepared in distilled water and stored at 20 C.
Mycobacterial and THP-1 seed stocks
M. tuberculosis H37Rv was cultured in Middlebrook 7H9
medium supplemented with 10% OADC, 2% glycerol, and 0.05%
Tween 80 (7H9C), and grown to mid to late log phase (OD600 0.6–
0.8). Mycobacterial cultures were ﬁrst washed with phosphate
buffered saline (PBS) containing 0.05% Tween 80 (PBST80) and
resuspended in 7H9C medium supplemented with 16% glycerol
stored at 80 C. THP-1 human monocytes (kindly provided by Dr J.
Muvva) were maintained in RPMI Glutamax medium supple-
mented with 10% FBS and antibiotics (R10+). Cells were washed
with R10+ and resuspended in 90% FBS containing 10% DMSO for
storage in liquid nitrogen tanks.A), and suberoylanilide hydroxamic acid (SAHA) against Mycobacterium tuberculosis
cterial growth medium were treated with INH or RIF (A), VPA at two different
ns (2.0 mM and 6.0 mM) (C). Concentrations of INH (0.729 mM) and RIF (1.215 mM)
l and RIF 1.0 mg/ml). The untreated growth control was used as the reference for
wo-way analysis of variance (ANOVA); *p < 0.05, **p < 0.01.
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Frozen seed stocks of M. tuberculosis were thawed, washed in
PBST80 buffer, resuspended in 7H9C medium to the required
density, and sonicated (Branson 2510 Ultrasonic Cleaner; Danbury,
CT, USA) for 2  10 s to disrupt mycobacterial cell clumping. The
bacterial culture was then transferred to a 96-well microtitre plate
for the drug sensitivity assay. Drugs (INH, RIF, VPA, SAHA) diluted
in 7H9C medium were added to the bacterial culture according to
the intended ﬁnal working concentration. No drugs were added to
the growth control wells. The bacterial cultures (with and without
drugs) were incubated at 37 C for 6 days. On days 0, 1, 3, and 6 of
the experiment, a serial dilution of the bacterial suspension was
prepared, plated on 7H11C medium, and incubated at 37 C for 3–4
weeks for colony-forming unit (CFU) enumeration.
Preparation of THP-1 macrophages, infection with M. tuberculosis,
and drug treatment
THP-1 human monocytes were differentiated into adherent
macrophages in 48-well tissue culture plates with R10+ medium
containing 100 ng/ml PMA (overnight incubation at 37 C with 5%
CO2). The macrophages were subsequently washed with antibiot-
ic-free RPMI medium supplemented with 10% FBS (R10). For
infection, frozen seed stocks of M. tuberculosis were thawed,
washed in PBST80 buffer, resuspended in R10 medium to the
required density, and sonicated (Branson 2510 Ultrasonic Cleaner)
for 2  10 s to disrupt cell clumping. M. tuberculosis suspension was
added to wells containing THP-1 macrophages at a multiplicity of
infection (MOI) of 5:1, centrifuged at 1500 rpm for 5 min to
increase phagocytosis, and incubated at 37 C with 5% CO2 for 4 h.
The macrophages were then washed with R10 medium and re-
incubated at 37 C with 5% CO2 following the addition of VPA/SAHA
and INH/RIF prepared in R10 medium. Control wells contained
drug-free R10 medium only. For M. tuberculosis CFU enumeration,
infected macrophages were ﬁrst lysed with PBS + 0.1% Triton X-100,
followed by the preparation of serial dilutions in PBST80 buffer for
spreading on 7H11C medium. Plates were incubated at 37 C for 3–
4 weeks prior to colony counting.
Statistical analysis
The statistical analysis was performed using GraphPad Prism
version 6 software. Mean and standard error of the mean (SEM)
values were plotted. A p-value of 0.05 or lower was considered
signiﬁcant. Each experiment was performed twice.
Results
Efﬁcacy of VPA and SAHA as single agents or in combination with INH/
RIF against extracellular M. tuberculosis
The doses of VPA and SAHA used in this study were selected on
the basis of previously published data (Archin et al., 2009; Han
et al., 2013a), whereas those used for INH (0.1 mg/ml or 0.729 mM)
and RIF (1.0 mg/ml or 1.215 mM) are the World Health Organiza-
tion-endorsed concentrations used in routine clinical diagnostics
using the BACTEC MGIT 960 system and Middlebrook media
(WHO, 2008). Initial testing was performed to determine whether
the HDIs have a direct effect on the viability of M. tuberculosis
grown in liquid 7H9C culture in the absence and presence of INH or
RIF after 1, 3, and 6 days post drug exposure (Figure 1). At 6 days
post exposure, INH treatment resulted in a 2.5-log CFU reduction,
while treatment with RIF alone afforded a 4.5-log CFU reduction
(Figure 1A). VPA treatment alone at 5.9 mM appeared to exert an
overall 1.5-log M. tuberculosis CFU reduction (Figure 1B). Incontrast, VPA at 1.18 mM had only a meagre inhibitory effect on
M. tuberculosis growth over the same period (Figure 1B). Treatment
with SAHA alone at 2.0 mM and 6.0 mM did not seem to affect M.
tuberculosis growth (Figure 1C).
The combination of INH and VPA (1.18 mM and 5.9 mM) did not
enhance the anti-mycobacterial potential of INH (Figure 2A).
However, INH + SAHA (2.0 mM and 6.0 mM) had anti-M. tuberculosis
activity at least as potent as INH alone, although a clear additional
effect was not seen (Figure 2B). RIF + VPA (1.18 mM) did not show a
much greater anti-mycobacterial effect compared to RIF alone,
although in combination with VPA at 5.9 mM, the bactericidal
activity of RIF was slightly increased (Figure 2C); the same held
true for RIF + SAHA (2.0 mM and 6.0 mM) (Figure 2D). Thus,
although VPA had a noticeable bactericidal effect on M. tuberculosis
growth, neither VPA nor SAHA had an adjunctive effect superior to
that of INH or RIF alone on extracellular M. tuberculosis.
VPA and SAHA enhance the activity of INH/RIF against intracellular M.
tuberculosis
Next, the impact of VPA and SAHA when exposed to
intracellular M. tuberculosis was assessed. This was done by ﬁrst
infecting THP-1 macrophages with M. tuberculosis and then
treating them with the drugs. Both HDIs had moderate bactericidal
activity at day 3 post treatment, with VPA (5.9 mM) exhibiting an
approximate 1.5-log reduction in M. tuberculosis load after 6 days of
treatment (Figure 3A). Treatment with SAHA (6.0 mM) afforded a
modest reduction of M. tuberculosis CFUs compared to the growth
control (approximately 0.5-log) after 3 days of exposure, but this
effect was not maintained up to day 6 (Figure 3A).
To assess whether the HDIs inﬂuenced an improvement in the
efﬁcacy of anti-TB drugs against intracellular M. tuberculosis, the
infected macrophages were treated with VPA and SAHA in
combination with INH or RIF. As already known, INH alone was
very potent at controlling the intracellular bacterial load over
6 days of treatment (1.5-log CFU reduction) (Figure 3B) – similar to
the bactericidal effect of VPA. The bactericidal effect of INH was
enhanced (2-log CFU reduction) when the infected macrophages
were exposed to VPA + INH over the same duration (Figure 3B).
When M. tuberculosis-infected macrophages were treated with
SAHA + INH, the bacterial CFU was reduced by 2.5-log, exceeding
the potentiating effect of VPA on INH, which was only 0.5-log
(Figure 3B). In general, the INH + VPA/SAHA combinations reduced
intracellular M. tuberculosis burden most drastically between days
3 and 6 of drug exposure (between 1.0- and 1.5-log) (Figure 3B).
RIF treatment led to a statistically signiﬁcant reduction in M.
tuberculosis load at day 1, which improved steadily over the 6-day
period of drug exposure (Figure 3C). RIF + VPA/SAHA also exerted a
similar bactericidal effect at day 1 of treatment, although this effect
appeared to be better than that of RIF alone at days 3 and 6 of
treatment, respectively (Figure 3C). Compared to INH + VPA/SAHA,
treatment of infected macrophages with RIF + VPA/SAHA markedly
reduced M. tuberculosis CFU counts between day 1 and day 3 of
exposure, suggesting accelerated anti-mycobacterial activity of
these combinations (Figure 3B,C). Furthermore, CFU reduction in
the presence of RIF + SAHA was about 1-log greater than that with
RIF alone after 3 days of treatment. Although not as effective as
RIF + SAHA, RIF + VPA afforded an additional 0.5-log CFU reduction
to RIF treatment alone at day 3.
In summary, VPA and SAHA can enhance the potency of RIF and
INH against intracellular M. tuberculosis in a shorter period.
Discussion
There are several important and novel ﬁndings from this study:
(1) these data are the ﬁrst to show that VPA and SAHA can enhance
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against intracellular M. tuberculosis; (2) VPA on its own possesses
some degree of bactericidal activity against extracellular, as well as
intracellular M. tuberculosis; (3) VPA in combination with INH or
RIF further enhances the anti-mycobacterial effect; (4) the
combination of RIF and SAHA enhances the reduction of
mycobacterial growth in liquid culture; (5) SAHA improves the
antibacterial activity of both RIF and INH against intracellular M.
tuberculosis in macrophages. The data show promise for the
potential adjunctive use of VPA and SAHA in combination with INH
or RIF for the treatment of drug-susceptible TB and provide the
background for further testing in drug-resistant TB.
VPA has already been reported to induce programmed cell
death via apoptosis, as well as autophagy in human cancer cells
and M. tuberculosis-infected macrophages (Schiebler et al., 2015;
Fu et al., 2010; Han et al., 2013b). Mechanistically, apoptosis
induced by VPA has been linked to its inhibition of eukaryotic
sirtuin nicotinamide adenine dinucleotide (NAD)-dependent
deacetylases (Sun et al., 2007). Interestingly, the M. tuberculosis
genome encodes Rv1151c, a sirtuin-like NAD-dependent deacety-
lase capable of activating acetyl coenzyme A synthetase (ACS) by
removing acetyl groups from lysine groups in the latter enzyme
(Xu et al., 2011). Deacetylation of ACS is necessary for the synthesis
of acetyl coenzyme A, a molecule with signiﬁcant biological
importance in central metabolism in all eukaryotes as well as
prokaryotes (Galdieri et al., 2014). It may therefore be hypothe-
sized that pharmacological inhibition of Rv1151c would inhibit ACS
deacetylation, inactivate its enzymatic activity, and consequently
disrupt bacterial growth, hinting at Rv1151c as a putative M.
tuberculosis target for VPA. This notion supports the observation in
this study of impaired M. tuberculosis growth when exposed to VPA
alone at 5.9 mM over 6 days, warranting further veriﬁcation.
Immunologically, VPA is known to starkly inhibit the produc-
tion of the pro-inﬂammatory cytokines tumour necrosis factorFigure 2. Bactericidal activity of valproic acid (VPA) and suberoylanilide hydroxamic aci
isoniazid (INH) or rifampicin (RIF). Extracellular M. tuberculosis in mycobacterial gro
concentrations of VPA (1.18 mM and 5.90 mM) (A, C) or SAHA (2.0 mM and 6.0 mM) (B, D) o
to the World Health Organization-recommended standards (INH 0.1 mg/ml and RIF 1.0
activity. Mean and SEM of two independent experiments analysed using two-way analalpha (TNF-a) and interleukin 6 (IL-6) by THP-1 macrophages and
human glioma cells (Ichiyama et al., 2000). VPA has also been
linked to alterations of the immune activation status of dendritic
cells, marked by reduced antigen presentation as well as their
ability to interact with T cells (Frikeche et al., 2012). A balanced
upregulation of TNF-a and IL-6 levels in the lung is associated with
a protective role in the early stages of TB infection; however,
exaggerated concentrations of either cytokine can be detrimental
during chronic and active TB disease (O’Garra et al., 2013;
Ravimohan et al., 2015). Furthermore, uncontrolled T-cell activa-
tion in pulmonary TB is destructive, and only warrants organ
damage and ultimately death (Zumla et al., 2015a). Thus, it may be
a better option to administer VPA to patients with severe
pulmonary TB in the later phase of treatment, which requires
dampening and/or modulation of lung immunopathology and ﬁne-
tuning of targeted anti-TB immune responses, in conjunction with
bacterial killing by anti-mycobacterial drugs.
Since treatment with SAHA alone did not directly affect M.
tuberculosis growth in liquid culture, it was assumed that
druggable targets inﬂuencing bacterial growth in axenic culture
that can be affected by SAHA are likely absent in M. tuberculosis.
Nevertheless, the meagre anti-mycobacterial effect of SAHA
treatment against M. tuberculosis growth in infected macrophages
hinted at bactericidal activity in a host-dependent fashion. It has
been shown previously that SAHA can trigger the generation of
reactive oxygen species such as superoxide anion and hydrogen
peroxide, which leads to DNA damage and the induction of
apoptosis (Petruccelli et al., 2011). SAHA-induced apoptotic cell
death has also been observed in acute myeloid leukaemia cell lines
(including THP-1 monocytes), which also coincided with reduced
cell viability after 2 days of exposure (Silva et al., 2013). Autophagy
induction by SAHA involves inhibition of the mammalian target of
rapamycin, as observed in human myeloid leukaemia cells as well
as HIV-1-infected macrophages (Campbell et al., 2015). Mored (SAHA) against M. tuberculosis in liquid culture when treated in combination with
wth medium were treated with INH or RIF in combination with two different
ver a 6-day period. Concentrations of INH (0.729 mM) and RIF (1.215 mM) correspond
 mg/ml). The untreated growth control was used as the reference for bactericidal
ysis of variance (ANOVA); ****p < 0.0001.
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antiviral activity of an experimental drug against WNV infection in
mice, in addition to reducing immunopathology in the brain
(Nelson et al., 2015). It is therefore tempting to speculate that theFigure 3. Efﬁcacy of valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA) ag
(INH) or rifampicin (RIF). M. tuberculosis-infected THP-1 macrophages were exposed to VP
6 days in cell culture medium. Concentrations of INH (0.729 mM) and RIF (1.215 mM) cor
and RIF 1.0 mg/ml). The untreated growth control was used as the reference for bactericid
analysis of variance (ANOVA); *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.apoptosis- and autophagy-inducing properties of VPA and SAHA
would reduce the number of M. tuberculosis-infected cells in the
host and expose the bacilli to anti-mycobacterial drugs such as INH
and RIF – as shown in this study. Therefore, VPA- or SAHA-inducedainst intracellular M. tuberculosis as single agents or in combination with isoniazid
A (5.9 mM) or SAHA (6.0 mM) alone (A), or in combination with INH (B) or RIF (C) for
respond to the World Health Organization-recommended standards (INH 0.1 mg/ml
al activity. Mean and SEM of two independent experiments analysed using two-way
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with intracellular M. tuberculosis, enabling increased killing of
bacteria by the drugs. However, the possibility of VPA and SAHA
having a direct impact on the intra-bacterial activation of INH and/
or RIF cannot be excluded, and therefore remains to be determined.
Taken together, the data suggest that VPA and SAHA further
potentiate the mycobactericidal activity of INH and RIF against
intracellular M. tuberculosis bacilli. Based on evidence in the
literature, this effect could possibly be achieved through a host-
directed mechanism of VPA/SAHA, by depriving the bacteria of
cellular reservoirs in the host via apoptosis and/or autophagy
(Schiebler et al., 2015; Fu et al., 2010; Han et al., 2013b). VPA has
been used for over half a century in healthcare systems globally
(WHO, 2015b). It is cheap and has an excellent safety proﬁle. SAHA
(vorinostat; marketed as Zolinza by Merck) has been included in an
access programme by the company for free or discounted
distribution to needy patients (Hematology ASo, 2015). Plasma
concentrations of VPA between 50 mg/l and 100 mg/l in patients
with epilepsy are considered therapeutic (Patsalos et al., 2008),
while SAHA reaches up to 658  439 ng/ml in patients with CTCL
(Kavanaugh et al., 2010). Thus, the clinically relevant bioavailability
of either drug should be reached in patients with TB. However, VPA
has been shown to have moderate interactions with INH; the latter
increases SAHA bioavailability in plasma (Medscape, 2017), which
has to be taken into consideration in the design of clinical trials.
There is growing interest in ‘repurposing’ clinically approved
drugs (based on their host-directed biological activity) for use as
adjunctive therapy for improving treatment outcomes in cancer
and infectious disease (Wallis and Hafner, 2015; Zumla et al.,
2015b; Mahon and Hafner, 2015; Schito et al., 2015; Zumla et al.,
2015c). Pertinent to TB, the contribution of host-directed therapies
(HDTs) to standard anti-TB drug therapy promises not only
improved treatment outcomes in the short term, but also reduced
long-term effects suffered by surviving individuals (Manji et al.,
2016; Zumla et al., 2015c). An international consortium of 64
clinical partners in ﬁve continents was formed in the spring of 2015
to bolster the progress of FDA-endorsed therapeutic agents with
promising anti-TB potential to bedside use (Zumla et al., 2015b).
Clinical evaluation of these drugs with regard to reducing the
duration of treatment and improving treatment outcomes for all
forms of TB, as well as the clinical determination of safety and the
pharmacological interactions between these repurposed drugs and
conventional TB drugs, is now required through randomized
clinical trials.
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